Premium
BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA
Author(s) -
Dickinson M.,
Briones Mejjide J.,
Herrera A.F.,
González Barca E.,
Ghosh N.,
Cordoba R.,
Rutherford S.C.,
Advani R.,
Bournazou E.,
LabriolaTompkins E.,
Friess T.,
Chesne E.,
BrouwerVisser J.,
Lechner K.,
Brennan B.,
Nueesch E.,
De Mario M.,
Hutchings M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.131_2629
Subject(s) - venetoclax , medicine , rituximab , diffuse large b cell lymphoma , regimen , clinical endpoint , oncology , follicular lymphoma , lymphoma , phases of clinical research , gastroenterology , chemotherapy , clinical trial , chronic lymphocytic leukemia , leukemia